Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Veronkia Bachanova, MD
University of Minnesota
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Illinois Cancer Center
Chicago, Illinois, United States
Completed - Indiana Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Withdrawn - University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Active, not recruiting - University of Minnesota
Minneapolis, Minnesota, United States
Veronika Bachanova, MDRecruiting - Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Timothy Voorhees, MDRecruiting - University of Wisconsin
Madison, Wisconsin, United States
Vaishalee Kenkre, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Sept 2018
- Primary completion
- 30 Sept 2026
- Completion
- 31 Jul 2027
- Last update posted
- 12 Jun 2026
- Registered enrollment
- 54
- Registry id
- NCT03681561
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.